FIELD: medicine.
SUBSTANCE: described are compressed tablets for oral administration containing Raltegravir in form of pharmaceutically acceptable salt. Tablet contains: (A) intra-granular component containing (i) effective amount of Raltegravir potassium salt, (ii) first super-expander, and (iii) binding agent; and (B) extra-granular component containing (i) second super-expander, (ii) excipient, and (iii) lubricating agent. Super-expander represents sodium croscarmellose, excipient represents microcrystalline cellulose or combination of microcrystalline cellulose and dibasic calcium phosphate, lubricating agent is magnesium stearate. Tablet contains neither atazanavir nor its pharmaceutically acceptable salt.
EFFECT: compressed tablets according to invention are characterized by high load by medicinal substance at acceptable size tablet.
11 cl, 1 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ORAL COMPOSITIONS OF CARDIAC SARCOMERE INHIBITORS | 2020 |
|
RU2823999C2 |
| CENICRIVIROC COMPOSITIONS AND METHODS FOR THEIR PRODUCTION AND APPLICATION | 2014 |
|
RU2633069C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING DORAVIRINE, TENOFOVIR DISOPROXIL FUMARATE AND LAMIVUDINE | 2016 |
|
RU2736941C2 |
| PHARMACEUTICAL COMPOSITIONS WITH CDC7 INHIBITOR | 2019 |
|
RU2810927C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING ANTIRETROVIRAL DRUG AND PHARMACOKINETICS IMPROVER | 2017 |
|
RU2745204C2 |
| SOLID FORMULATIONS OF OSPEMIFENE | 2005 |
|
RU2675624C2 |
| NEW ANTIRETROVIRAL COMBINATION | 2008 |
|
RU2508105C2 |
| AMORPHOUS SOLID DISPERSION COMPRISING TAXANE, TABLET COMPRISING SAME, AND METHOD FOR PREPARING SAME | 2015 |
|
RU2684632C2 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF CYSTIC FIBRIOSIS | 2019 |
|
RU2822220C2 |
| ANTI-TUBERCULOSIS STABLE PHARMACEUTICAL COMPOSITION IN FORM OF DISPERSIBLE TABLET CONTAINING GRANULATED ISONIAZID AND GRANULATED RIFAPENTINE, AND METHOD FOR PREPARING IT | 2014 |
|
RU2694056C2 |
